Your session is about to expire
← Back to Search
mRNA-1273 for Pneumococcal Disease
Study Summary
This trial will study if it is safe to give two vaccines for COVID-19 and pneumococcal disease at the same time or if it is better to space them out.
- Pneumococcal Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 2013 Patients • NCT05047770Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other ongoing trials using mRNA-1273?
"Currently, there are 52 active clinical trials studying mRNA-1273. Of these, 19 are in Phase 3. The vast majority of the locations for these trials are in Miami, Florida; however, there are 1,351 total sites running clinical trials for this medication."
What is the largest sample size for this clinical trial?
"This particular clinical trial is not recruiting at this time. It was initially posted on December 1st, 2022 and last updated on November 3rd, 2022. There are other 22 studies exploring pneumococcal infections and 52 for mRNA-1273 that are presently looking for participants."
mRNA-1273 is most commonly administered for which purpose?
"mRNA-1273 is a medication used to treat streptococcus pneumoniae, which can also lead to conditions such as otitis media. It is effective against serotype 6b and 23f."
Are there still available slots where patients can participate in this trial?
"Unfortunately, this study has completed recruitment for participants. The trial was initially posted on 1/12/2022 and last edited on 11/3/2022. However, there are other ongoing clinical trials that might be of interest. For example, 22 different trials are actively recruiting patients with pneumococcal infections and 52 mRNA-1273 trials are also enrolling individuals."
Share this study with friends
Copy Link
Messenger